Antiretroviral Drugs
In plain English
The notice doesn't say
Who holds it now
Last won by Amgen Ltd and Fresenius Kabi Ltd and Celltrion Healthcare and 2 more in Aug 2026, for £7.8m.
- UstekinumabAmgen Ltd, Fresenius Kabi Ltd, Celltrion Healthcare and 2 more £7.8m
- Generic Drugs – Injections/Infusions 2Accord UK Ltd, Aspire Pharma Ltd, B Braun Medical Ltd and 13 more £7m
- Transitional Drugs 7Amgen Ltd, Celltrion Healthcare, Fresenius Kabi Ltd and 7 more £20.2m
What you're up against
- The same firms have won it the last 3 times Kestrel found: expect them to bid again, and to know the work well.
- 26 different firms won this buyer's 3 awards for this kind of work in 2026.
- It last went for £7.8m in 2026.
- The last award named 5 suppliers: it may be a framework, where many firms are chosen.
The notice as published
Supply of Antiretroviral Drugs which are all shortly due to lose their patent exclusivity (or have previously lost their exclusivity) and therefore will have competition available in the UK.